Versatility and scalability of Noile technology
Our Approach
In pursuing the development of cancer immunotherapy, Noile-Immune Biotech strives to establish truly effective new treatment built on our technology. While we are continuously conducting our own activities in research and development, we are also actively seeking strategic collaborations with academia and to build business partnerships with bioventures and pharmaceutical companies, thereby creating new opportunities to apply our technology and expand our new platforms.
Versatility and scalability of PRIME technology
PRIME technology is designed to act on T cells and the host immune system to enhance their ability to kill tumor cells. It provides a platform that can be adapted to various cancer immunotherapies. In addition to CAR-T cells, we are investigating ways to apply PRIME technology in other cell therapies, including TCR-T cells. We believe that by conducting these trials with various collaborators, we will be able to expand the range of cancer types targeted, which will lead to the delivery of effective treatments to a greater number of cancer patients.
Examples of New Applications
Noile's Application
TCR-T cell therapy
In a cancer immunotherapy called “TCR-T cell therapy,” a gene for a cancer antigen-specific TCR, instead of CAR, is transduced into T cells so that the T cells can specifically recognize and attack tumor cells expressing the antigen.
PRIME technology can be applied to TCR-T cell therapy to enhance the treatment efficacy.
Noile's Application
Allogeneic CAR-T cell therapy
Unlike autologous CAR-T cell therapy, in which the patient’s own T cells are used to prepare CAR-T cells, allogeneic CAR-T cell therapy uses T cells from a donor to prepare CAR-T cells. The advantage is that an allogeneic CAR-T cell stock can be manufactured in advance and can be quickly administered to patients when needed. Also, the cost of treatment can be reduced if large quantities of CAR-T cells can be prepared from high-quality T cells.
Allogeneic CAR-T cell therapy, however, could induce rejection responses, as observed in bone marrow and other organ transplants. Allogeneic CAR-T cells need to be modified by genome-editing technologies or other strategies to prevent rejection responses.
PRIME technology can be applied to allogeneic CAR-T cell therapy to enhance its treatment efficacy.
Noile's Application
Oncolytic virus therapy
An oncolytic virus infects cancer cells and induces cell death. PRIME technology can be applied to oncolytic virus therapy to enhance treatment efficacy.